Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
12/06/2024 | 14:00 | Business Wire | Evolus Broadens International Presence with Launch of Nuceiva® (botulinum toxin type A) in Spain | NASDAQ:EOLS | Evolus Inc |
11/06/2024 | 22:05 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:EOLS | Evolus Inc |
07/06/2024 | 23:00 | Business Wire | Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | NASDAQ:EOLS | Evolus Inc |
07/06/2024 | 01:01 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:EOLS | Evolus Inc |
06/06/2024 | 23:45 | Edgar (US Regulatory) | Form 144 - Report of proposed sale of securities | NASDAQ:EOLS | Evolus Inc |
20/05/2024 | 14:30 | Business Wire | Evolus Announces Positive Data from Pivotal Trial for First Two Evolysse™ Dermal Filler Products at 2024 SCALE Meeting | NASDAQ:EOLS | Evolus Inc |
15/05/2024 | 14:30 | Business Wire | Evolus Celebrates Fifth Anniversary of Launching its Flagship Product Jeuveau® at the Women’s Wear Daily Beauty CEO Summit | NASDAQ:EOLS | Evolus Inc |
10/05/2024 | 15:10 | Business Wire | Evolus’ Sandra Beaver Named Orange County Business Journal’s Public Company CFO of the Year | NASDAQ:EOLS | Evolus Inc |
07/05/2024 | 23:00 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] | NASDAQ:EOLS | Evolus Inc |
07/05/2024 | 22:05 | Business Wire | Evolus Reports First Quarter 2024 Results and Provides Business Update | NASDAQ:EOLS | Evolus Inc |
23/04/2024 | 22:30 | Business Wire | Evolus to Report First Quarter Financial Results on May 7, 2024 | NASDAQ:EOLS | Evolus Inc |
17/04/2024 | 22:05 | Business Wire | Evolus Announces Publication of Safety and Duration Data from Phase 2 Study for “Extra-Strength” 40U Formulation of Jeuveau® | NASDAQ:EOLS | Evolus Inc |
26/03/2024 | 13:00 | Business Wire | Evolus to Participate in the 23rd Annual Needham Virtual Healthcare Conference | NASDAQ:EOLS | Evolus Inc |
11/03/2024 | 14:00 | Edgar (US Regulatory) | Form 424B5 - Prospectus [Rule 424(b)(5)] | NASDAQ:EOLS | Evolus Inc |
11/03/2024 | 12:00 | Business Wire | Evolus Announces Pricing of $50.0 Million Underwritten Offering of Common Stock | NASDAQ:EOLS | Evolus Inc |
07/03/2024 | 22:58 | Edgar (US Regulatory) | Form S-8 - Securities to be offered to employees in employee benefit plans | NASDAQ:EOLS | Evolus Inc |
07/03/2024 | 22:42 | Edgar (US Regulatory) | Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] | NASDAQ:EOLS | Evolus Inc |
07/03/2024 | 22:05 | Business Wire | Evolus Reports Record Fourth Quarter and Full Year 2023 Financial Results; Reaffirms 2024 Guidance | NASDAQ:EOLS | Evolus Inc |
01/03/2024 | 14:30 | Business Wire | Evolus Announces Results from European Head-to-Head Filler Trial | NASDAQ:EOLS | Evolus Inc |
27/02/2024 | 14:30 | Business Wire | Evolus to Participate in Upcoming Leerink Partners and Barclays Investor Conferences | NASDAQ:EOLS | Evolus Inc |
22/02/2024 | 22:30 | Business Wire | Evolus to Report Fourth Quarter and Year End 2023 Results and Provide Business Update on March 7, 2024 | NASDAQ:EOLS | Evolus Inc |
16/01/2024 | 23:28 | Business Wire | Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2023 Net Revenue, Achieving Record Results and Exceeding Expectations; Issues 2024 Guidance | NASDAQ:EOLS | Evolus Inc |
11/01/2024 | 12:18 | IH Market News | Wall Street Highlights: Mastercard’s Financial Rise, Citigroup’s $3.8 Billion Charges, and More | NASDAQ:EOLS | Evolus Inc |
04/01/2024 | 22:05 | Business Wire | Evolus Announces the Appointment of Nareg Sagherian to Vice President, Head of Global Investor Relations and Corporate Communications | NASDAQ:EOLS | Evolus Inc |
20/12/2023 | 14:00 | Business Wire | Evolus Enters into Licensing Agreement with Symatese to Exclusively Distribute Next-Generation Dermal Fillers in Europe | NASDAQ:EOLS | Evolus Inc |
12/12/2023 | 11:50 | IH Market News | Hasbro Job Cuts, Oracle’s Stock Decline, Google’s Epic Antitrust Loss, and More | NASDAQ:EOLS | Evolus Inc |
07/11/2023 | 22:16 | Business Wire | Evolus Reports Record Third Quarter 2023 Financial Results and Phase II Data for Extra-Strength 40U Formulation of Jeuveau® | NASDAQ:EOLS | Evolus Inc |
06/11/2023 | 14:45 | Business Wire | “Extra-Strength” 40U Formulation of Jeuveau® Demonstrates Effects Lasting 26 Weeks in Phase II Data Presented at 2023 ASDS Annual Meeting | NASDAQ:EOLS | Evolus Inc |
01/11/2023 | 13:45 | Business Wire | Evolus to Participate in November Investor Conferences | NASDAQ:EOLS | Evolus Inc |
25/10/2023 | 14:45 | Business Wire | Evolus to Report Third Quarter 2023 Results | NASDAQ:EOLS | Evolus Inc |